Carboplatin-gemcitabine Versus Cisplatin-gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer: a Prospective Randomized Trial

Condition: Urinary Bladder Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT05822934

Sponsor: Assiut University

Phase: Phase 3


  • Age: minimum 18 Years maximum N/A
  • Gender: All

Inclusion Criteria:

  • All patients diagnosed with muscle invasive urinary bladder cancer that can receive chemotherapy are included the criteria are
  • • Age above 18 years,
  • Pathologically proven urinary bladder cancer,
  • Patients with clinical stages T2-4a N0-3 M0,
  • Patients with good renal and liver functions
  • patients with no distant metastases,
  • no other malignancy (double malignancy).
  • Performance status 0-1 according to ECOG performance status scale.
  • Patients with no contraindications for radiotherapy.

Exclusion Criteria:

  • • performance status 2-4 according to ECOG performance status scale.
  • patients refuse to receive chemotherapy,
  • patients not eligible to receive chemotherapy due to liver or renal impairment or thrombocytopenia,
  • patients with M1 disease.

View trial on